166 related articles for article (PubMed ID: 37775106)
1. Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.
Zhou Y; Naci H; Chen D; Bai L; Shi L; Guan X; Wagner AK
BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37775106
[TBL] [Abstract][Full Text] [Related]
2. Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'.
Grössmann N; Wolf S; Rothschedl E; Wild C
ESMO Open; 2021 Jun; 6(3):100166. PubMed ID: 34087744
[TBL] [Abstract][Full Text] [Related]
3. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
4. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.
Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW
Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727
[TBL] [Abstract][Full Text] [Related]
5. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
6. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
8. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C
Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700
[TBL] [Abstract][Full Text] [Related]
9. Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials.
Ding L; Yuan X; Wang Y; Shen Z; Wu P
BMJ Open; 2024 Jun; 14(6):e077108. PubMed ID: 38851227
[TBL] [Abstract][Full Text] [Related]
10. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
[No Abstract] [Full Text] [Related]
11. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
12. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
17. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
Gyawali B; de Vries EGE; Dafni U; Amaral T; Barriuso J; Bogaerts J; Calles A; Curigliano G; Gomez-Roca C; Kiesewetter B; Oosting S; Passaro A; Pentheroudakis G; Piccart M; Roitberg F; Tabernero J; Tarazona N; Trapani D; Wester R; Zarkavelis G; Zielinski C; Zygoura P; Cherny NI
ESMO Open; 2021 Jun; 6(3):100117. PubMed ID: 33887690
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores.
Broekman KE; Jalving M; van Tinteren H; Sessa C; Reyners AKL
Cancer Treat Rev; 2018 Sep; 69():233-242. PubMed ID: 30098485
[TBL] [Abstract][Full Text] [Related]
19. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Kiesewetter B; Dafni U; de Vries EGE; Barriuso J; Curigliano G; González-Calle V; Galotti M; Gyawali B; Huntly BJP; Jäger U; Latino NJ; Malcovati L; Oosting SF; Ossenkoppele G; Piccart M; Raderer M; Scarfò L; Trapani D; Zielinski CC; Wester R; Zygoura P; Macintyre E; Cherny NI;
Ann Oncol; 2023 Sep; 34(9):734-771. PubMed ID: 37343663
[TBL] [Abstract][Full Text] [Related]
20. Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.
Knapen DG; Cherny NI; Zygoura P; Latino NJ; Douillard JY; Dafni U; de Vries EGE; de Groot DJ
ESMO Open; 2020 Sep; 5(5):e000681. PubMed ID: 32893188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
